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Abstract
Background: Inflammation around cell bodies of primary sensory neurons and retinal ganglion
cells enhances expression of neuronal growth-associated genes and stimulates axonal regeneration.
We have asked if inflammation would have similar effects on corticospinal neurons, which normally
show little response to spinal cord injury. Lipopolysaccharide (LPS) was applied onto the pial
surface of the motor cortex of adult rats with or without concomitant injury of the corticospinal
tract at C4. Inflammation around corticospinal tract cell bodies in the motor cortex was assessed
by immunohistochemistry for OX42 (a microglia and macrophage marker). Expression of growth-
associated genes c-jun, ATF3, SCG10 and GAP-43 was investigated by immunohistochemistry or
in situ hybridisation.
Results: Application of LPS induced a gradient of inflammation through the full depth of the motor
cortex and promoted c-Jun and SCG10 expression for up to 2 weeks, and GAP-43 upregulation
for 3 days by many corticospinal neurons, but had very limited effects on neuronal ATF3
expression. However, many glial cells in the subcortical white matter upregulated ATF3. LPS did
not promote sprouting of anterogradely labelled corticospinal axons, which did not grow into or
beyond a cervical lesion site.
Conclusion: Inflammation produced by topical application of LPS promoted increased expression
of some growth-associated genes in the cell bodies of corticospinal neurons, but was insufficient to
promote regeneration of the corticospinal tract.
Background
Evidence from studies on dorsal root ganglion (DRG)
neurons and retinal ganglion cells (RGCs) suggests that
the induction of an inflammatory response around the
cell bodies of axotomised neurons enhances the regenera-
tion of their axons. Injection of corynebacterium into
DRG prior to dorsal root injury produces a fourfold
increase in the number of regenerating axons [1]. Simi-
larly, injection of zymosan into the vitreous body of the
eye induces extensive but transient regeneration of RGC
axons in the crushed optic nerve [2]. Lens injury has sim-
ilar effects on RGC axonal regeneration, probably because
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it stimulates the accumulation of macrophages in the ret-
ina [2]. Furthermore, adult RGCs grown in media condi-
tioned by activated macrophages also display enhanced
neurite growth [3].
Against this background we have investigated the possibil-
ity that LPS-induced inflammation around the cell bodies
of corticospinal tract neurons would enhance their expres-
sion of growth-associated genes (c-jun, ATF3, SCG10 and
GAP-43) and promote regeneration of their axons follow-
ing spinal cord injury. It is of particular importance and
interest to investigate these questions in relation to corti-
cospinal neurons because their axons constitute the major
descending motor pathway, and because they display very
poor regenerative responses to injury. Thus corticospinal
neurons do not regenerate axons to any significant extent
along peripheral nerve grafts inserted into the spinal cord
or brainstem [4-6] and display upregulation of growth-
associated genes only after intracortical lesion of their
axons and not after spinal injury [7,8].
Results
Assessing LPS-induced inflammation in cortex
Coronal sections through the motor cortex to which LPS
had been applied were immunostained with OX42, an
antibody that recognizes the type 3 complement receptor
(CR3) in mononuclear phagocytes, which is upregulated
by activated microglia and macrophages [9]. In unoper-
ated brains and on the side opposite to LPS application,
and in sham-operated animals (dura opened; no LPS
applied +/- Gelfoam), highly ramified (presumably rest-
ing) microglia were present throughout the cortex. In
brains in which the dura had been opened contralateral to
the side of LPS application, there was some accumulation
of rounded OX42-positive cells at the pial surface in the
first 7 days after treatment but deeper layers contained
ramified microglia (Figs. 2a, c, e). In LPS-treated cortex,
microglial morphology was altered from the ramified
form typical of the quiescent state, to a rounded amoe-
boid shape, with thicker proximal processes and loss of
distal ramification (Figs 2b, d). At 3 days after LPS appli-
cation microglia numbers in layer V were increased, with
a mean of 177 cells per unit area (136,000 µm2), 91.4%
of which were activated, compared to a mean of 69 cells
in the contralateral cortex – of which only 0.5% were acti-
vated (Table 1). In the animals in which Fluorogold was
used to retrogradely label corticospinal tract (CST) neu-
rons, activated OX42-positive microglia were closely asso-
ciated with the cell bodies of identified CST neurons in
layer V (Fig. 3). However, the inflammatory response to
LPS was variable. In most animals, microglial activation
was seen in all layers of the cortex beneath the site of LPS
application, and extending up to 2 mm on either side, for
up to one week after application. In a few animals micro-
glial activation was only evident in the outer two thirds of
the cortex. Inflammation around layer V pyramidal neu-
rons was always apparent beneath the site of LPS applica-
tion. Two weeks after application, rounded, amoeboid
microglia were rare and microglia with a ramified mor-
phology predominated in both the ipsilateral and contral-
Schematic diagrams showing experimental design and proce- dures Figure 1
Schematic diagrams showing experimental design 
and procedures. a. Unilateral application of lipopolysaccha-
ride (LPS) to the pial surface of motor cortex through a cra-
nial burrhole with sham operation on the contralateral side, 
to investigate the inflammatory response and expression of 
growth-associated proteins. b. Unilateral LPS application to 
the pial surface and injection of Cholera toxin B or place-
ment of Fluorogold (FG) (retrograde tracers) into the con-
tralateral corticospinal tract (CST) at C4 or C6 respectively, 
to identify CST neurons displaying changes in growth-associ-
ated protein expression. c. Application to the pial surface of 
LPS with injection of biotinylated dextran amine (BDA; anter-
ograde tracer) into motor cortex and transection of contral-
ateral CST. LPS application omitted in control animals.BMC Neuroscience 2006, 7:8 http://www.biomedcentral.com/1471-2202/7/8
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Microglial responses to LPS application Figure 2
Microglial responses to LPS application. Coronal sections of motor cortex, immunoreacted with OX42 antibody to visu-
alise microglia/macrophages 3 days (Figs 2a, b), 7 days (Figs 2c, d) and 2 weeks (Figs 2e, f) after unilateral application of LPS to 
the pial surface (Figs 2b, d, f) or sham operations on the contralateral (contra), control side (Figs 2a, c, e). Here and in all other 
figures, the pial surface is at the top and all sections are photographed immediately below the craniotomy, with the same expo-
sure for all pairs of images taken at each survival time. Microglia from layer V are illustrated at higher magnification in the 
insets. Note that microglia are present throughout the full depth of cortex at all time points and are ramified in the control but 
are rounded and amoeboid and more numerous in the LPS-treated cortical tissue 3 days and 7 days after LPS application. The 
numerous immunoreactive cells at the pial surface on both sides of the brain (Figs 2a, b) are likely to be macrophages of hae-
matogenous origin induced by local damage due to craniotomy. Note the reduction in number of such cells at 7 days and that 
very few remain at two weeks. Scale bar in Fig. 2a = 200 µm and also applies to Fig. 2b; scale bar in Fig. 2c = 200 µm and also 
applies to Figs 2d – f (Figs 2a and b are of greater magnification than Figs. 2c – f); scale bar in the inset to Fig. 2a = 50 µm and 
applies to all insets.BMC Neuroscience 2006, 7:8 http://www.biomedcentral.com/1471-2202/7/8
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ateral cortex (Figs 2e, f). There were 75.3 microglia per
unit area in control cortex, 0.4% of which were activated,
compared to 79.3 microglia per unit area, of which 2.9%
were activated, in LPS-treated cortex. At one month, the
ipsilateral and contralateral cortex appeared identical in
all animals, with only ramified microglial cells apparent.
Thus, 500 µg of LPS was sufficient to produce inflamma-
tion around layer V pyramidal neurons in all animals by
24 hours, which was maximal at 3 days and had subsided
by two weeks after application.
From 3 days to 2 weeks after the application of LPS, GFAP-
positive astrocytes in the LPS-treated cortex showed
hypertrophy of their processes and GFAP immunofluores-
cence near the inflamed pial surface was more intense
(Fig. 4b) than in the contralateral cortex, (Fig. 4a) or in
unoperated controls. Astrogliosis was less marked in
deeper layers of cortex.
Expression of growth-associated genes by corticospinal 
tract neurons
Injection of CTB into the spinal cord at C4 invariably
labelled layer V pyramidal cell bodies in the contralateral
motor cortex. Sections immediately adjacent to those
reacted for CTB were reacted for c-Jun, ATF3 or SCG10
(e.g. Figs 5b, d). Other sections were reacted for both CTB
and a growth-associated protein, allowing identification
of the protein and CST neurons in the same section (Fig.
8).
Control cortex
Making a burr hole in the skull and opening the dura had
some effect on c-Jun and ATF3 expression for up to 3 days.
In unoperated cortex, c-Jun was weakly expressed in cells
in layers II, III and V. There was a small increase in c-Jun
expression by cells in layers I, II, III and V (mostly or
entirely neurons) directly underneath the burr hole even
without LPS application (Fig. 5a). In unoperated cortex
there was no ATF3 expression whereas in sham-operated
controls, ATF3 was expressed by very small numbers of
layer I cells directly underneath the burr hole (<5 per sec-
tion). These ATF3-expressing cells had abnormal nuclei
and were possibly apoptotic but could not be unequivo-
cally identified. Expression of SCG10 protein and GAP-43
mRNA were not affected by opening of the dura. SCG10
was weakly expressed, in layer V neurons only, in the cor-
Table 1: Number and morphology of cortical layer V microglia after sham-operation or LPS application
Sham-operated LPS-treated
Ramified microglia Activated microglia Ramified microglia Activated microglia
3 days after LPS Mean number 69 0.3 15.3 162
% of total 99.5 0.5 8.6 91.4
14 days after LPS Mean number 75.3 0.3 77 2.3
% of total 99.6 0.4 97.1 2.9
1 month after LPS Mean number 67 0 72 0
% of total 100 0 100 0
Note: All microglia within an area of 400 µm × 340 µm (136,000 µm2) defined by a counting frame superimposed over a digitised image of layer V 
were counted and identified as either ramified (quiescent) or activated. Numbers represent means of 3 counts; % indicates relative proportions of 
ramified and activated microglia.
Table 2: Expression of cortical growth-associated genes in unoperated, sham-operated and LPS-treated animals
Group c-Jun expression cortical 
layers
ATF3 expression cortical 
layers
SCG10 expression 
cortical layers
GAP-43 expression 
cortical layers
Unoperated animals -/+ - -/+ +
II, III V II – VI
Control animals (dura 
opened)
++ - / + +
II, III, V I, II V II – VI
Cortex contralateral to 
LPS application
++ - / + +
II, III, V I, II V II – VI
LPS-treated cortex +++ ++ + ++
II, III, V1 I, II2, V4 & white matter glia2 V1 II – VI3
Note: Superscript numbers refer to duration of expression of the growth-associated gene after LPS application: 1 for up to 2 weeks; 2 for up to 7 
days; 3 for up to 3 days; 4 for up to 24 hoursBMC Neuroscience 2006, 7:8 http://www.biomedcentral.com/1471-2202/7/8
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tex contralateral to LPS application, and in sham-operated
and unoperated animals. GAP-43 mRNA was present in
neurons in all layers of the cortex, but most strongly in
layers IV and V, contralateral to LPS application, in sham-
operated and unoperated animals, confirming our previ-
ous findings [8]. The presence or absence of Gelfoam
made no difference to the expression of growth-associated
genes in the cerebral cortex.
LPS-treated cortex
C-Jun
From 24 hours to two weeks after LPS application c-Jun
was markedly upregulated in most neurons of layers II, III
and V of the motor cortex (Figs 5b, d). Retrograde label-
ling with CTB (Fig. 5 insets) and retrograde labelling com-
bined with immunohistochemistry for c-Jun (Fig. 8)
showed that CST neurons in layer V were among cells
upregulating c-Jun in response to LPS application. By 1
month after application (Fig. 5f) there were no detectable
differences between treated and control cortex.
ATF3
By 24 hours after application of LPS, ATF3 was upregu-
lated in a very few neurons, confined to the region under
the burr hole, and in numerous glia in the subcortical
white matter. As in the sham-operated animals, ATF3-pos-
itive nuclei in layer I were often abnormally shaped. ATF3-
positive neurons in layers II to VI were extremely sparse
(<8 per section on the treated side; none on the contralat-
eral side), but retained a normal morphology. ATF3 was
upregulated in layer V pyramidal neurons but only in rel-
atively small numbers of such cells. Expression of ATF3 in
subcortical white matter glia was much more extensive
than the neuronal expression; ATF3-positive nuclei were
present up to 400 µm into the contralateral hemisphere
and for 2 mm lateral to the area of LPS application (not
illustrated). At 3 days, neurons expressing ATF3 were
almost entirely confined to layers I and II under the burr
hole and to glia in subcortical white matter (Figs 6a, b, c).
This upregulation was variable and appeared to correlate
with the level of inflammation. ATF3 expression was
weaker at 7 days (Fig. 6d) and had disappeared by 2 weeks
(Fig. 6e). Thus, ATF3 immunoreactivity was seen in only a
few layer V pyramidal neurons in animals with a maximal
(i.e. full cortical thickness) inflammatory response and
only at 24 hours after application.
SCG10
SCG10 was weakly upregulated by layer V pyramidal neu-
rons and by no other cells. This effect was seen from 24
hours to 2 weeks after LPS application (Fig. 7). The cell
bodies displaying upregulation of SCG10 were identified
as CST neurons (Fig. 8b).
GAP-43 mRNA
GAP-43 mRNA was upregulated in neurons in layers II –
VI of LPS-treated cortex, 3 days after application (Fig. 9b),
most conspicuously in layer V. After 7 days (Figs 9e, f), 2
weeks (not illustrated) or 1 month (Fig. 9g, h) GAP-43
expression resembled that in unoperated cortex.
Effect of CST injury in cervical spinal cord
Transection of the CST at C4 contralateral to LPS applica-
tion had no detectable effect on the expression of c-Jun,
ATF3 or SCG-10 (not illustrated). Because of these nega-
tive findings we did not investigate possible effects of
combining LPS treatment with C4 CST injury in the ani-
mals used to study GAP-43 mRNA expression by in situ
hybridisation.
Sprouting of corticospinal tract axons at the lesion site
Application of LPS to motor cortex had no obvious effect
on the numbers and morphology of microglia around the
lesion site in the spinal cord, compared with controls
(data not shown). Three weeks after spinal cord lesion,
injured CST axons, anterogradely labelled with BDA, ter-
minated proximal to the lesion site, many with swollen
axonal tips, in both LPS-treated and control animals (Figs
10a, b). No axons were seen to grow into or distal to the
Microglial response around identified CST neuron after LPS  application Figure 3
Microglial response around identified CST neuron 
after LPS application. Coronal section of OX42-immuno-
reacted motor cortex (layer V) 3 days after LPS administra-
tion and simultaneous application of Fluorogold to a lesion of 
contralateral cord at C6. Note the very close association 
between the microglial cell (red) and the retrogradely-
labelled (blue) CST neuronal cell body. Scale bar = 10 µm.BMC Neuroscience 2006, 7:8 http://www.biomedcentral.com/1471-2202/7/8
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lesion cavity or to bypass the lesion site, or send branches
around it. Thus, application of LPS to the cortex appeared
to produce no enhancement of axon regeneration into or
around the lesion site. There was no statistically signifi-
cant difference between control and LPS-treated animals
in either the 'total sprouting ratios' (t-test, p = 0.12) or the
'lesion site sprouting ratios' (t-test, p = 0.32). These data,
summarised in Table 3, suggest that application of LPS to
motor cortex has no effect on the sprouting response or
regeneration of CST axons across a lesion. The application
of LPS to cortex did not cause a reduction of labelled CST
axons in the medulla (Table 3; Fig. 10c). This result dem-
Astrocytic response to LPS application Figure 4
Astrocytic response to LPS application. Coronal sections of GFAP-immunostained motor cortex below the area of LPS 
application (Fig. 4b) or sham operation (Fig. 4a) on the contralateral (contra), control side, 3 days after application of LPS. Note 
that astrocytes are present throughout the full depth of cortex and are more brightly fluorescent in the LPS-treated cortex, 
with thicker processes than in the control cortex. Scale bar in Fig. 4a = 200 µm and also applies to Fig. 4b.
Table 3: Quantification of CST axons
Lesion site axon total Branching points Medulla axon total Total sprouting ratio Lesion site sprouting 
ratio
LPS 1 133 52 466 0.11 0.39
LPS 2 123 100 788 0.13 0.81
LPS 3 146 54 685 0.08 0.36
LPS 4 301 128 519 0.25 0.42
LPS group mean ± SEM 614.5 ± 74.5 0.14 ± 0.04 0.5 ± 0.1
Con 1 150 162 998 0.16 1.08
Con 2 273 162 602 0.27 0.59
Con 3 200 78 323 0.24 0.39
Con 4 138 98 439 0.22 0.71
Control group mean ± SEM 590.5 ± 147.5 0.22 ± 0.02 0.69 ± 0.15
Student's t-test p value for LPS-treated vs. control animals 0.89 0.12 0.32
Notes: BDA-labelled axons (and branch points) in 4 LPS-treated animals and 4 control animals (LPS not applied) were counted at two sites: 1) in 9 
horizontal sections through the cervical spinal cord 0.4 mm rostral to the lesion site, in a 60 µm wide counting frame (labelled axons and branch 
points); 2) in transverse sections through the medulla (number of labelled axons in pyramid). Total sprouting ratio is the ratio between the number 
of branch points and the total number of labelled CST axons at the level of the medulla. Lesion site sprouting ratio is the ratio between branch 
points and labelled axons at the same level (0.4 mm rostral to the lesion site); SEM = standard error of the meanBMC Neuroscience 2006, 7:8 http://www.biomedcentral.com/1471-2202/7/8
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Expression of c-Jun after LPS application Figure 5
Expression of c-Jun after LPS application. Coronal sections of motor cortex 3 days (Figs 5a, b), 2 weeks (Figs 5c – e) and 
1 month (Fig. 5f) after unilateral application of LPS, or sham operation (Figs 5a, c), immunoreacted for c-Jun or CTB (insets to 
Figs 5b, d and f). Note that, at 3 days c-Jun is detectable in layers II, III and V at low levels immediately below the craniotomy on 
the control side, but is almost undetectable more medially and laterally, and that c-Jun immunoreactivity is much stronger on 
the treated side, predominantly in layers II, III and V, immediately below the site of LPS application. Note also the marked 
increase in c-Jun immunoreactivity in layers II, III and V immediately below the burr hole and site of LPS application in Fig. 5d 
compared to the corresponding contralateral cortex in Fig. 5c. The framed area of layer V in Fig. 5d is enlarged in Fig. 5e to 
show details of immunostained nuclei. The insets to Fig. 5b and d are taken from the section immediately serial to the ones 
shown in Figs 5b and d and demonstrates that retrogradely labelled CST neurons occupy the same area (in layer V) as neurons 
displaying upregulation of c-Jun expression. Some of the retrogradely labelled cells in Fig. 5d are shown at greater magnification 
in the inset to Fig. 5f. Note also that at one month, c-Jun immunoreactivity in layers II and III of the experimental side still 
involves areas medial and lateral to the site of LPS application with almost no c-Jun detectable in layer V (c-Jun immunoreactiv-
ity in the contralateral cortex is weak and largely confined to layers II and III: not shown). Scale bar = 500 µm and applies to 
Figs 5a – d and f); bar in Fig. 5e = 20 µm; bar in Fig. 5f inset = 50 µm.BMC Neuroscience 2006, 7:8 http://www.biomedcentral.com/1471-2202/7/8
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Expression of ATF3 after LPS application Figure 6
Expression of ATF3 after LPS application. Coronal sections of motor cortex immunoreacted for ATF3, 3 days (Figs 6a, 
b, c), 7 days (Fig. 6d) and 2 weeks (Fig. 6e) after LPS application. Fig. 6a shows both the experimental and the medial part of the 
control cortex (midline at the vertical arrow) and demonstrates ATF3 immunoreactivity directly under the area of the burr 
hole and in the subcortical white matter on the experimental side. The superficial upregulation is localised, but immunoreactive 
cells in the white matter extend for 2 mm laterally and 400 µm across the midline. There is no ATF3 immunoreactivity in cor-
tical neurons located in layers III to VI or in the contralateral (control) cortex. Fig. 6b is enlarged from the boxed area of cor-
tex directly under the site of LPS application in Fig. 6a. Note the irregular shape of ATF3-positive nuclei, suggesting possible 
damage or apoptosis. Fig. 6c is enlarged from the boxed area of white matter in Fig. 6a. ATF3-positive nuclei are seen arranged 
in a linear fashion, suggesting that they are white matter glial cells. Fig. 6d, 7 days after LPS application shows reduced ATF3 
immunoreactivity directly under the LPS application site (top arrow) and in the subcortical white matter (bottom arrow). Fig. 
6e shows no ATF3 immunoreactivity 2 weeks after LPS application. The inset is from the immediately serial section, directly 
beneath the LPS application site and demonstrates CST neurons retrogradely labelled with CTB. No ATF3 immunoreactivity 
was seen in the area of cortex where the CTB-labelled CST neurons were located. Scale bar in Figs 6a and e = 500 µm; bar in 
Fig. 6b = 50 µm and also applies to Fig. 6c; bar in Fig. 6d = 200 µm.BMC Neuroscience 2006, 7:8 http://www.biomedcentral.com/1471-2202/7/8
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Expresssion of SCG10 after LPS application Figure 7
Expresssion of SCG10 after LPS application. Coronal sections of motor cortex immunoreacted for SCG10 (except for 
insets), 1 week (Figs 7a – d) and 1 month (Figs 7e, f) after LPS application. Control, contralateral cortex is shown in Figs 7a, c 
and e, LPS-treated cortex in Figs 7b, d and f. Note increased SCG10 immunoreactivity in layer V cells at one week in Fig. 7b 
compared to contralateral cortex (Fig. 7a), and absence of immunoreactivity in more superficial cortex. Fig. 7c is enlarged from 
layer V in Fig. 7a and Fig. 7d is enlarged from layer V in Fig. 7b. One month after LPS application there is only a background 
level of SCG10 immunoreactivity in layer V cells of both contralateral (Fig. 7e) and ipsilateral (Fig. 7f) cortex. The insets are 
from immediately serial sections to Figs 7e and 7f and show retrogradely CTB-labelled CST neurons in layer V. Bar in Fig. 7a = 
200 µm and also applies to Figs 7b, e, f and insets; bar in Fig. 7c = 50 µm and also applies to Fig. 7d.BMC Neuroscience 2006, 7:8 http://www.biomedcentral.com/1471-2202/7/8
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onstrates that the uptake and anterograde transport of
BDA by CST neurons was unaffected by LPS-induced
inflammation.
Discussion
The inability of axotomised CST neurons to upregulate
growth-associated gene expression is believed to be one
cause of their failure to regenerate axons [10,11]. We have
shown here that application of LPS onto the pial surface
of motor cortex produced inflammation – demonstrated
by activation of microglia – in most cases throughout the
entire depth of cortex and also increased expression of
growth-associated genes in some CST neurons. ATF3
expression was upregulated for 1 day (but in very few
cells), GAP-43 for 3 days, c-Jun for 2 weeks and SCG10 for
2 weeks in neurons within the inflamed cortex. However,
in animals treated with LPS and having a concomitant C4
CST injury there was neither an obvious increase in CST
axon sprouting nor any regeneration across or around the
lesion site.
Does inflammation around neuronal perikarya stimulate 
axonal regeneration?
Two experimental models provide evidence that inflam-
mation around neuronal perikarya can stimulate axonal
regeneration in vivo. Injection of Corynebacterium
extracts into the DRG both enhances the ability of the cen-
tral axons of DRG cells to regenerate after injury [1] and
stimulates upregulation of GAP-43 and c-jun in their cell
bodies [12], thus mimicking some of the effects of a con-
ditioning peripheral nerve lesion. Similarly, Leon et al. [2]
have shown that zymosan, a powerful inflammatory
agent, injected into the vitreous body of the eye in adult
rats, produces inflammation in the retina, upregulation of
GAP-43 expression by RGCs and enhanced regeneration
of RGC axons following optic nerve injury. The interpreta-
tion of these experiments has been questioned by Fischer
et al. [13] who suggested that zymosan may injure the
lens, releasing factors that stimulate axonal regeneration.
However, it has been shown recently that activated mac-
rophages secrete a protein that, in conjunction with
cAMP, acts as a powerful promoter of neurite outgrowth
[3]. We have shown that LPS-induced inflammation also
stimulates neuronal expression of growth-associated
genes in the cerebral cortex. However, we did not find
enhancement of CST axonal regeneration, perhaps
because of an insufficiently strong inflammatory response
in layer V, or possibly because of local inhibitors at the
injury site.
Co-localisation of retrograde label and c-Jun or SCG10 Figure 8
Co-localisation of retrograde label and c-Jun or SCG10. CTB (red) in the cell bodies of CST neurons co-localised with 
c-Jun (Fig. 8a) or SCG10 (Fig. 8b) (green) in coronal sections of the motor cortex (layer V), 3 days after application of LPS and 
simultaneous injection of CTB into the CST at C4. Note that not all layer V neurons expressing c-Jun in their nuclei also show 
co-localisation with CTB (Fig. 8a). There is a higher degree of co-localisation between SCG10 and CTB (Fig. 8b). Confocal 
microscopy; scale bar = 20 µm and applies to both images.BMC Neuroscience 2006, 7:8 http://www.biomedcentral.com/1471-2202/7/8
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GAP-43 mRNA expression after LPS application Figure 9
GAP-43 mRNA expression after LPS application. Coronal sections of motor cortex hybridised with GAP-43 mRNA 
probe 3 days (Figs 9a – d), 7 days (Figs 9e, f) and 1 month (Figs 9g, h) after unilateral application of LPS (Figs 9b, d, f, h) or sham 
operations to the contralateral (control) side (Figs 9a, c, e, g). Background levels of GAP-43 mRNA are seen in contralateral 
(control) cortex at 3 days but stronger expression is apparent in layers II–V of LPS-treated cortex. Areas of layer V in Fig. 9a 
and b are enlarged in Fig. 9c and d to better show differences in hybridisation signals. By 7 days (Figs 9e and 9f), GAP-43 mRNA 
expression appears to be identical on both sides, and remains so one month after LPS application (Figs 9g and h). Scale bar in 
Fig. 9a = 500 µm and also applies to Fig. 9b; scale bar in Fig. 9c = 50 µm and also applies to Fig. 9d; scale bar in Fig. 9e = 200 µm 
and also applies to Figs 9f – h.BMC Neuroscience 2006, 7:8 http://www.biomedcentral.com/1471-2202/7/8
Page 12 of 21
(page number not for citation purposes)
Anterograde labelling of CST axons after spinal cord injury and LPS application Figure 10
Anterograde labelling of CST axons after spinal cord injury and LPS application. Horizontal sections through spinal 
cord injury sites (Figs 10a, b), and a transverse section through the medulla (Fig. 10c) 21 days after lesion of the CST at C4 with 
either simultaneous injection of BDA into contralateral motor cortex (Control) or injection of BDA into and application of LPS 
onto motor cortex (LPS). In both the LPS-treated (Fig. 10b) and control tissue (Fig. 10a), end bulbs are seen at the tips of large 
numbers of axons. There is little sign of axon branching into the contralateral CST, and the labelled axons extending into the 
lesion site are located in a strand of spared tissue that extends no more than 50 µm. No axons appear to circumnavigate or 
regenerate beyond the lesion site. The white boxes correspond to the counting frame windows. Fig. 10c shows BDA-labelled 
CST axons in the pyramid of the medulla (midline at arrow). All images are confocal; * = lesion site; R = rostral; L = lateral; P = 
pyramid; scale bar in Fig. 10a = 100 µm and also applies to Fig. 10b; bar in Fig. 10c = 200 µm.BMC Neuroscience 2006, 7:8 http://www.biomedcentral.com/1471-2202/7/8
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LPS-induced cerebral inflammation
LPS, an endotoxin derived from the cell wall of E. coli, is
a potent inflammatory agent [14]. It has been extensively
used in previous experimental studies in the central nerv-
ous system (CNS) and other tissues [15]. The Toll-like
receptor 4 (TLR-4) acts as an LPS receptor on microglia
[16,17], but is absent from cortical neurons [18].
Although the effects of applying LPS to the surface of the
cerebral cortex have not been studied previously, it has
been shown that injection of LPS into the cortex results in
recruitment of macrophages, activation of local microglia
and, later, activation of astrocytes [19,20]. Neutrophils
however are not recruited, in contrast to what occurs after
LPS injection into peripheral tissues [15], which may
explain the absence of overt damage to the brain. LPS
applied to the cortical surface in this study markedly
increased the number of rounded OX42-positive cells at
the surface of the brain and in the meninges (which were
presumably peripheral macrophages – see Fig. 2), and
activated microglia, increasing their number throughout
the motor cortex (Table 1). In most animals, there was a
clear gradient of activation from superficial to deep, sug-
gesting that LPS activated microglia in a concentration-
dependent manner. LPS can also attract circulating mono-
cytes into the brain but it is not clear to what extent circu-
lating monocytes entered the cortex in our experiments, as
there are no reliable cell markers that distinguish macro-
phages from microglia. Furthermore, the astrogliosis
shown by GFAP immunofluorescence in the cortex to
which LPS was applied confirms the inflammatory effect
of the LPS.
Zymosan has been used to produce inflammation in the
retina and promote regeneration in crushed optic nerve. It
may be significant that LPS injection into the vitreous
body was not a sufficient stimulus to induce regeneration
of optic axons [2]. However, the eyeball is a highly
'immune-privileged' site, and more resistant to inflamma-
tion than cerebral cortex. Zymosan particle injection into
cortex caused substantial cavity formation and a glial scar
[21], whereas single injections of LPS into cortex caused
minimal cavitation [19,22]. Chronic infusion of LPS into
hippocampus produced a focal necrotic lesion at the infu-
sion site, with a surrounding region showing activation of
astrocytes and macrophages [23]. Our aim was to cause
no damage to the CST cell bodies or their axons within the
cortex; we therefore applied LPS to the surface of the cor-
tex. There was no sign of necrosis and it is extremely
unlikely that LPS applied to the pial surface would have
caused axonal injury to CST neurons. If LPS application
had resulted in axonal injury, there would have been
reductions in the numbers of BDA-labelled axons in the
medulla. The counts of labelled CST axons in LPS-treated
versus control animals (no significant differences: Table
3) show that direct axonal injury did not occur. Further-
more, CST neurons showing upregulation of SCG10 and
c-Jun were retrogradely labelled from the spinal cord after
LPS application, demonstrating that their axons were
intact (Fig. 8).
Role of perineuronal macrophages and microglia in axonal 
regeneration
Macrophages enter DRGs after a peripheral conditioning
lesion and may play a role in the survival or regeneration
of axotomised neurons [24-26]. Microglial activation also
occurs in the CNS around facial, hypoglossal and spinal
motor neurons after axotomy [27,28], probably because
of the release of macrophage-colony stimulating factor by
the injured neurons [29]. In contrast to regenerating facial
nucleus neurons, non-regenerating intrinsic CNS neurons
do not attract activated microglia after axotomy [30-32].
However, most evidence suggests that the accumulation
of microglia around axotomised neurons is unnecessary
for axonal regeneration [33,34] and it has been suggested
that the main role of microglia around axotomised neu-
rons is in immune surveillance [35,36]. Nonetheless, even
if perineuronal macrophages or microglia are not essen-
tial for the regeneration of motor axons, the data from
optic nerve regeneration experiments suggests that they
may be capable of enhancing the cell body response and
thus of promoting regeneration in less regeneration-com-
petent neurons.
Growth-associated genes, axonal regeneration and 
perineuronal inflammation
The transcription factor c-Jun has been implicated in both
neuronal cell death and survival after injury [37-39] and
is consistently upregulated after axotomy in regenerating
neurons [40-42]. Recently it has been shown that in mice
lacking neuronal c-Jun, both cell death and axonal regen-
eration after axotomy are reduced [42]. ATF3 is also a tran-
scription factor that is induced in many cell types by a
range of stresses [43]. ATF3 has been shown to prevent cell
death and to be a neurite growth-promoting factor for cul-
tured neurons, apparently acting through HSP27 [44]. Co-
localisation studies indicate that ATF3 and c-jun mRNA
are co-expressed in several types of neuron after injury.
Transfecting ATF3 alone into two neuron-like cell lines
did not cause neurite outgrowth; c-Jun expression alone
caused some outgrowth, but co-expression of both ATF3
and c-Jun greatly increased neurite outgrowth [45].
It has been hypothesised that GAP-43 and SCG10 are
important for axonal elongation, through their role in
cytoskeletal dynamics [46-48]. Motor and DRG neurons
upregulate these molecules soon after axotomy. Expres-
sion decreases markedly following target reinnervation,
but remains high if reinnervation is prevented, suggesting
that contact with target tissues regulates expression of
these molecules.BMC Neuroscience 2006, 7:8 http://www.biomedcentral.com/1471-2202/7/8
Page 14 of 21
(page number not for citation purposes)
The effects of ATF3, GAP-43 and SCG10 individually on
axonal regeneration in vivo are difficult to assess. No
axonal regeneration experiments have been reported on
ATF3 knockout mice [49]. GAP-43 deficient mice show
neuroanatomical abnormalities but their CNS appear to
be grossly normal and with normal axon growth rates
[50]; hence GAP-43 is unlikely to be essential for axonal
growth but probably is required for successful axonal
pathfinding. Transgenic overexpression of individual
growth-associated molecules has induced some sprouting
[51], but has not turned non-regenerating neurons into
regeneration-competent cells, even into favourable envi-
ronments such as implanted segments of peripheral nerve
or Schwann cells [52,53]. However, overexpression of
GAP-43 and CAP23 together, greatly enhanced the ability
of ascending dorsal column axons to regenerate into
peripheral nerve grafts placed in the spinal cord without a
conditioning peripheral lesion [54]. No SCG10 knockout
animals have been described.
The molecules we have studied are only examples of a
large range of neuronal molecules that may be required
for regeneration of axons. Tetzlaff et al. [55] showed that
although cut rubrospinal axons do not regenerate; the
injury results in prolonged increased levels of GAP-43 in
their cell bodies, from which they concluded that it is their
failure to maintain tubulin and actin synthesis that pre-
vents regeneration. Since individual growth-associated
genes are unlikely to greatly stimulate axonal regenera-
tion, finding a mechanism whereby a whole cascade of
such molecules could be upregulated may be necessary to
bring about axonal regeneration in otherwise refractory
CNS neurons. It seems clear that further studies are
needed into the mechanisms of upregulating transcrip-
tion factors that control growth associated proteins.
We have not included in this report the results of studies
on the effects of applying zymosan to the pial surface of
the motor cortex because we found that half of the ani-
mals thus treated developed cortical damage, often severe,
in layers I to IV, that made it impossible to distinguish the
effect of inflammation from other destructive processes
(unpublished findings). Interestingly, the CST neurons in
these zymosan-treated rats displayed expression patterns
of growth-associated proteins that were almost identical
to those seen in LPS-treated rats at corresponding time
points. As zymosan is more potent an inflammmogen
than LPS, it is possible that LPS stimulated a maximal
expression of growth-associated proteins in CST cell bod-
ies without causing overt damage. Furthermore, the esti-
mated number of cells that upregulated c-Jun, SCG10 and
GAP-43 after LPS application was far greater than the
number of BDA-labelled fibres in our spinal cord injury
experiments, suggesting that the cell bodies of these
labelled axons had probably upregulated growth-associ-
ated genes.
An intracortical injection of a solution of LPS might
induce a stronger inflammation closer to the cell bodies of
CST neurons, but such an approach is problematic
because direct tissue damage may elicit responses which
mask/confound those due to the induction of an inflam-
matory response by cortical application of LPS. We carried
out experiments in which small amounts of LPS were
injected into deep cortex. Such injections resulted in nei-
ther a detectably greater inflammatory response nor
greater upregulation of growth-associated proteins in
layer V (unpublished results). It remains to be seen
whether other approaches to inducing cortical inflamma-
tion would promote a stronger and longer-lasting expres-
sion of growth-associated proteins, with the effect of
stimulating CST axon regeneration.
It is possible that CST axotomy interrupts target derived
regeneration-suppressing signals, and this may potentiate
the effects of LPS in promoting growth-associated gene
expression. However, our results showed no difference in
growth associated protein expression between axot-
omised and intact CST neurons. Previous work in this lab-
oratory has demonstrated that cervical axotomy is
insufficient to induce upregulation of growth associated
genes, although axotomy within the cortex (close to the
cell body) does so [8]. However, promoting enhanced cell
body responses by proximal axotomy is unlikely to be of
practical value because of the very large distance over
which the CST axons would have to regrow to effect func-
tional reconnection.
It is noteworthy that the inflammatory response induced
by LPS resulted in more extensive upregulation of ATF3 in
glia than in neurons. It is interesting to compare this find-
ing with observations on ATF3 expression in glial cells
during Wallerian degeneration. Following dorsal root
injury, ATF3 is strongly upregulated in Schwann cells
around degenerating axons in the dorsal root, but not in
the CNS glial cells around the degenerating axons in the
dorsal column [56].
Conclusion
We carried out these experiments to test the hypothesis
that inflammation would induce the expression of
growth-associated genes in the cell bodies of CST neurons
and would consequently increase the regenerative
response after CST injury. We found that application of
LPS to the motor cortex induced upregulation of c-jun,
ATF3, SCG10 and GAP-43 in some neurons. However, the
response was generally greatest in superficial layers, as was
the degree of inflammation. Nonetheless, we have dem-
onstrated that perineuronal inflammation produced by aBMC Neuroscience 2006, 7:8 http://www.biomedcentral.com/1471-2202/7/8
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single application of LPS can cause CST neurons to upreg-
ulate a range of growth-associated proteins, although the
number of cells which responded in this way was limited
and the effects most obvious in the first few days after
application. Axonal regeneration was not enhanced. The
failure of CST neurons to show enhanced axon regenera-
tion may be due to the inflammatory stimulus not being
strong enough or not lasting long enough. There was var-
iation between animals in the extent of inflammation/
microglial activation produced by the standard dose (500
µg) of LPS applied to the cortical surface, and inflamma-
tion was always less marked in layer V than near the sur-
face of the cortex. The absence of a widespread
upregulation of ATF3 in CST neurons may have been the
result of insufficient inflammation in layer V, which may
have limited the expression of the full repertoire of down-
stream genes necessary for regeneration. Sustained, or
increased inflammation deeper in the cortex may be nec-
essary to induce a sufficiently strong and prolonged
upregulation of growth-associated genes that would lead
to a vigorous regenerative response to injury by CST neu-
rons.
Methods
Animals and surgery
Adult female Sprague-Dawley rats (220–250 g; n = 66)
were anaesthetised with a mixture of halothane, nitrous
oxide and oxygen. All surgery was performed under asep-
tic technique and was approved by the local ethical com-
mittee and by the Home Office under UK animal
experimental legislation.
Application of lipopolysaccharide
The scalp was incised in the midline and bilateral craniot-
omies performed to expose the surface of the motor cortex
(localised according to the atlas of Paxinos and Watson,
[57]). A 3 mm × 4 mm piece of parietal bone was removed
from the cranium, centred 3 mm caudal to the bregma
and 2 mm from the midline. The dura was opened and
500  µg of LPS from Escherichia coli, serotype 055:B5
(Sigma, UK) was applied – as a powder – to the exposed
pial surface of the right hemisphere (Fig. 1a). The powder
dissolved to a paste on contact with the CSF and was kept
in place by application of Gelfoam (Johnson & Johnson,
Skipton, UK), which was anchored to the cranium with
histoacryl glue (B. Braun, Melsungen AG, Germany). In
preliminary experiments it was found that if less than 500
µg of LPS was applied to cortex, inflammation did not
consistently extend as deep as layer V. As a control for the
effects of surgery, the contralateral cortex was exposed but
LPS was not applied. The scalp incision was closed with
Michel clips and the animals allowed to recover in an
incubator. Survival times were 1 day (n = 3), 3 days (n =
8), 7 days (n = 6), 14 days (n = 4) and 1 month (n = 4)
after LPS application. A further 9 LPS-treated animals (sur-
vival 3 days to 1 month) also received a left corticospinal
tract (CST) transection lesion at the time of LPS applica-
tion in order to determine if concomitant axotomy is a
requirement for growth associated gene expression. A C3/
4 laminectomy was performed and microscissors used to
cut the area between the left dorsal root entry zone and
the right CST down to a depth of 2 mm. The dura was
closed and the wound closed in layers, and the animals
allowed to recover in an incubator. In 6 other animals
(survival 3, 7 and 14 days), the motor cortex was exposed
unilaterally, Gelfoam applied on top of the burrhole and
the scalp then closed (without the application of LPS). In
3 further animals (survival 3 days) the motor cortex was
exposed but neither LPS nor Gelfoam were applied prior
to closing the scalp, as a control for the possibility that the
surgical procedure or the application of Gelfoam contrib-
uted to any of the effects observed (see Table 4).
Table 4: Animal utilisation
Survival time Cortical LPS (with 
SCI) for IHC
Cortical LPS with 
retrograde 
labelling
Cortical LPS for 
ISH
Cortical LPS with 
SCI and 
anterograde 
labelling
SCI with 
anterograde 
labelling
Controls (Gelfoam 
not applied)
1 day 3
3 days 5 (+3) 5 4 (+1 control) 3 (+3)
7 days 4 (+2) 4 1
14 days 2 (+2) 2 3 2
21 days 44
1 month 2 (+2) 1 4
TOTAL 16 (+9) = 25 8 15 (+1) 4 4 6 (+3)
Notes: IHC = immunohistochemistry; ISH = in situ hybridisation; SCI = spinal cord injury (denotes animals with unilateral transection of 
corticospinal tract at C4).
Controls were animals in which the dura was opened unilaterally without application of LPS (in 6 of these animals Gelfoam was applied to the 
cortex; in 3 others no Gelfoam was applied). In addition, control exposure of the left cerebral cortex was carried out in all animals with unilateral 
LPS application.
This Table does not include 6 positive control animals in which the expression of growth associated proteins was examined in the facial nucleus 
following facial nerve injury and it also excludes 12 animals used in pilot studies to determine the optimal dose of LPS.BMC Neuroscience 2006, 7:8 http://www.biomedcentral.com/1471-2202/7/8
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Retrograde tracing with Cholera Toxin B (CTB) or 
Fluorogold (FG)
In order to identify the neuronal cell bodies giving rise to
the CST in animals treated with LPS, the contralateral cer-
vical spinal cord was injected with CTB (List laboratories,
Inc, Campbell, CA, USA) in a further 5 rats. Three days
before the animals were killed, a laminectomy was per-
formed at C3/4, the dura opened, and 1.5 µl of CTB was
slowly injected into the CST, through a Hamilton syringe
attached to a fine glass pipette (Fig. 1b). The dura and
wound were closed in layers and the animals allowed to
recover in an incubator. The survival periods after LPS
application for these animals were 3 days (n = 2), 14 days
(n = 2) and one month (n = 1). Coronal sections of brain
were processed for the visualisation of both growth asso-
ciated proteins and CTB (described below). In a further 3
animals (survival 3 days) Gelfoam impregnated with 1.5
µl of Fluorogold (Molecular Probes, Oregon, USA)
(diluted to 2% in sterile water) was inserted into a contral-
ateral (left) C6 corticospinal tract lesion at the same time
as LPS was applied to the cortex. Coronal sections of the
brains of these three animals were immunostained with
OX42 antibody in order to examine the relationships
between microglia and CST cell bodies after LPS treatment
(see below).
Corticospinal tract injury and anterograde tracing with 
Biotinylated Dextran Amine (BDA)
To study the effect of cell body inflammation on CST axon
regeneration, the CST was lesioned at the same time as
LPS was applied to the cerebral cortex (n = 4) or the dura
opened without application of LPS (n = 4), and at the
same time BDA was injected into the cortex to label CST
axons (Fig. 1c). The spinal cord was exposed at C3/4 by
laminectomy and the area between the left dorsal root
entry zone and the midline was cut to a depth of 2 mm
with microscissors, and the cut extended to cross the mid-
line, undercutting the midline spinal artery to minimise
ischaemic damage. Overlying muscle and skin was
sutured. Immediately thereafter, a midline incision was
made over the skull, a 4 mm × 2 mm burr hole made over
the right parietal cortex, the dura opened and LPS powder
(500 µg) placed on the pial surface (LPS application omit-
ted in control animals). Then BDA (Molecular Probes,
Oregon, USA) dissolved in 0.1 M phosphate-buffered
saline (PBS) (10% solution) was injected into the cortex,
about 1 mm below the pial surface, through a Hamilton
syringe attached to a glass micropipette. The micropipette
was introduced into the cortex at a very shallow angle
from the rostral edge of the burr hole and advanced 4 mm
in a caudal direction, and parallel to the cortical surface.
The BDA solution (2.5 µl) was injected as the pipette was
slowly withdrawn to its entry point. The injection was
then repeated, via the same entry point, but with the
micropipette directed 1 mm medial to the initial injection
track, and repeated again, with the pipette directed 1 mm
lateral, thus delivering a total of 7.5 µl BDA solution. The
exposed area of cortex was covered with Gelfoam, the
wound sutured and the animal checked upon recovery to
ensure that no unexpected deficits were present. Survival
time for all animals in this group was three weeks.
Any inflammatory response due to damage induced by
the relatively large volumes of BDA injected would occur
in both LPS-treated and control animals and would there-
fore not significantly impact on or obscure effects due to
LPS.
Facial nerve injury
As a positive control, expression of growth-associated pro-
teins was induced in facial nucleus neurons by facial nerve
injury. In 6 adult rats, anaesthetised as described above, a
1 cm skin incision was made posterior to the right ear, and
the facial nerve exposed and crushed for 10 seconds with
watchmakers' forceps proximal to its branch point. The
skin incision was closed with Michel clips and the animals
allowed to recover in an incubator. All were killed after
seven days.
Perfusion and histological processing
Animals were overdosed with halothane and intraperito-
neal pentobarbitone, and perfused transcardially with
200 ml of PBS followed by 350 ml of 4% paraformalde-
hyde in 0.1 M PBS buffer. The brain was removed and
immersed in fixative solution for 2 hours. Dissected tissue
specimens were then cryoprotected for 40 hours in PBS
containing 30% sucrose.
Antibodies
ATF3
polyclonal (raised in rabbit); dilution 1:800; source –
Santa Cruz, CA, USA.
c-Jun
polyclonal (raised in rabbit); dilution 1:5000; source –
Dr. A. Behrens (Cancer Research, UK), gift.
SCG10
polyclonal (raised in rabbit); dilution 1:3000; source –
Dr. G. Grenningloh (University of Lausanne, Switzer-
land), gift.
OX42
monoclonal (raised in mouse); dilution 1:3000; source –
Serotec, Oxford, UK.
GFAP
monoclonal (raised in mouse); dilution 1:800; source –
Sigma, St. Louis, Missouri, USABMC Neuroscience 2006, 7:8 http://www.biomedcentral.com/1471-2202/7/8
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CTB
polyclonal (raised in goat); dilution 1:100,000 – List Bio-
logical Laboratories, CA, USA.
Single label immunohistochemistry
Coronal sections of brain through the motor cortex and
pons (containing the facial nucleus) were cut at 40 µm
using a freezing microtome and collected in 0.1 M PBS.
Care was taken to ensure that every section to be reacted
for growth-associated protein expression was immediately
adjacent to a section reacted for CTB. All sections were
then washed in 0.3% H2O2 for 15 minutes to remove
endogenous peroxidase, followed by 3 × 5 minute PBS
washes (or 0.1 M tris-buffered saline (TBS) + 0.05%
Tween 20 (TNT), for OX42 and CTB). Then followed a
one hour wash in blocking solution, using 1% bovine
serum albumin (BSA), 0.1% Triton-X and 10% normal
goat serum in PBS (for sections to be reacted with the anti-
bodies against ATF3, c-Jun and SCG10) or 2% horse
serum in TBS (for OX42, GFAP and CTB). Serial sections
were incubated with primary antibody (made up in
appropriate blocking solution) against ATF3, c-Jun
SCG10, OX42, GFAP or CTB for 72 hours at 4°C. Sections
of motor cortex and pons incubated with the appropriate
blocking solution rather than with primary antibody,
served as negative controls. After 3 washes in PBS/TNT,
sections to be immunoreacted for ATF3, c-Jun and SCG10
were incubated for 2 hours in 1:200 rat-adsorbed, goat
anti-rabbit biotinylated secondary antibody; sections to
be immunoreacted for CTB were incubated in 1:200 horse
anti-goat biotinylated secondary antibody and sections to
be immunoreacted for OX42 or GFAP were incubated in
horse anti-mouse biotinylated secondary antibody (all
diluted in appropriate blocking solution). After 3 further
washes, ATF3, c-Jun, SCG10 and CTB sections were
reacted with an avidin-biotin complex (ABC) kit
(Vectastain, Burlingame, CA, USA) for 2 hours, again
washed in PBS and finally reacted with 0.04% 3-3' diami-
nobenzidine tetrahydrochloride in 0.015% H2O2 in TBS
until a brown reaction product appeared (usually about
12–15 minutes). OX42 sections were washed in TNT,
incubated in streptavidin-conjugated horseradish peroxi-
dase (streptavidin-HRP) (Vector Laboratories, Burlin-
game, CA, USA) for 1 hour at 1:200 in TBS, washed in TNT
buffer, reacted with Tyramide Cy3 (NEN Life Science
Products, Boston, USA) for 30 minutes at 1:400 in TBS
and then washed in TBS. GFAP sections were washed in
TNT, incubated in horse anti-mouse IgG FITC conjugate
(Sigma, St. Louis, Missouri, USA) at 1:100 for 1 hour and
then washed in TBS. Sections for fluorescence microscopy
were mounted onto agar-coated slides and coverslipped
immediately with glycerol containing 1,4-diazabicy-
clo[2,2,2]octane (DABCO). Sections reacted with ABC
were dried overnight and dehydrated through ascending
concentrations of alcohol, followed by Histoclear
(National Diagnostics, Georgia, USA) before being
mounted onto slides and coverslipped with DPX (Merck,
Poole, UK).
Double label immunohistochemistry
The steps followed were the same as for OX42 immun-
ofluorescence processing until the stage of incubation in
primary antibody solution. At this point, primary anti-
body against ATF3, c-Jun or SCG10 was mixed with the
antibody against CTB, made up in blocking solution con-
taining 2% normal horse serum. Sections were then rinsed
in TNT (3 × 5 minutes), incubated for 2 hours in 1:200
horse anti-goat biotinylated secondary antibody (made
up in TNT), rinsed again in TNT and incubated for 1 hour
in a mixture of 1:200 streptavidin-HRP and 1:100 donkey
anti-rabbit FITC (made up in blocking solution). After 3
further TNT washes, sections were reacted for 30 minutes
in 1:400 Tyramide Cy 3, washed in TBS, mounted onto
slides and coverslipped immediately with DABCO.
The steps followed for retrograde labelling with Fluoro-
gold were the same as for single OX42 immunofluores-
cence processing up to the stage of incubation with the
ABC kit. At this point, sections were instead incubated
with 1:200 horse anti-mouse Alexa Fluor 568 (Molecular
Probes, Invitrogen Corporation, Paisley, UK) for one
hour, washed in TBS, mounted onto slides and cover-
slipped immediately with DABCO.
Digital images were taken using a Zeiss Axiophot micro-
scope equipped with Openlab image processing software.
BDA labelling immunohistochemistry
Cryoprotected spinal cord or brainstem tissue was frozen
in Tissue-Tek (Sakura, Zoeterwoude, Netherlands) cooled
with dry ice. Serial horizontal cryostat sections through
the entire CST and transverse sections of the medulla
through the pyramids, were cut at 40 µm and collected in
0.05 M TBS. The free floating sections were rinsed in 0.05
M TBS and 0.5% Triton X-100 (TBST), incubated in 0.3%
H2O2 for 15 minutes, rinsed in TBST (2 × 10 minutes) and
incubated at 1:200 dilution of ABC overnight at 4°C. They
were then rinsed in TBST, incubated in Tyramide Cy3 at
1:400 for 30 minutes, rinsed in 0.05 M TBS and mounted
as above.
In situ hybridisation
An additional 16 animals were used for in situ hybridisa-
tion studies. Of these, 15 had unilateral LPS application to
the pial surface of motor cortex as described above and 1
had a unilateral opening of dura only (as a control). They
were sacrificed at 3 days (n = 4, plus 1 control), 7 days (n
= 4), 14 days (n = 3) and 1 month (n = 4) after LPS appli-
cation, by lethal overdose of halothane and intraperito-BMC Neuroscience 2006, 7:8 http://www.biomedcentral.com/1471-2202/7/8
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neal pentobarbitone. Their brains were removed and
immediately frozen in Tissue-tek cooled with dry ice.
GAP-43 cRNA antisense probes were obtained from
pcDNA-GAP-43, which contains the 680 base pair open
reading frame of rat GAP-43 cDNA and labelled with dig-
oxigenin according to the manufacturer's recommenda-
tions using an RNA labelling kit (Boehringer Mannheim,
Germany), as described by Mason et al. [58]. Sections
derived from animals at all survival times were processed
under identical conditions, at the same time.
In situ hybridisation was carried out as previously
described [59,60]. Coronal cryostat sections of motor cor-
tex directly under the area of LPS application were cut at a
nominal thickness of 12 µm, thaw-mounted onto slides
coated with 3-aminopropyltriethoxy-silane, and fixed
with 4% paraformaldehyde in PBS overnight at 4°C. After
washing in PBS, sections were treated with 0.1 M HCl, and
washed in PBS, incubated in 0.1 M triethanolamine con-
taining 0.25% acetic anhydride, and then washed with
PBS, dehydrated in an ascending ethanol series, and air
dried. Prehybridisation was carried out at 37°C for 3
hours with a mixture of prehybridisation buffer/deionised
formamide 1:1 (containing 50% formamide, 25 mM eth-
ylenediaminetetra-acetic acid (EDTA), 50 mM, pH 7.6
Tris-HCl, 2.5× Denhardt's solution, 0.25 mg/ml tRNA
(Boehringer Mannheim), and 20 mM NaCl). The digoxi-
genin-labelled GAP-43 probe was prepared at a concentra-
tion of 3 µl/ml with hybridisation buffer containing 50%
formamide, 20 mM Tris-HCl (pH 7.50), 1 mM EDTA, 1×
Denhardt's solution, 0.5 mg/ml tRNA, 0.1 mg/ml poly (A)
RNA (Sigma), 0.1 M DTT, and 10% dextran sulfate.
Hybridisation was performed overnight at 62°C. After
hybridisation, sections were washed in 0.2× standard
saline citrate (SSC), containing 30 mM NaCl, and 3 mM
Na-citrate, pH 7.0 and then in 0.1× SSC/50% formamide
at the hybridisation temperature. Sections were equili-
brated with buffer 1 (100 mM Tris-HCl, 150 mM NaCl,
pH 7.5), incubated in modified buffer 2 (1% Boehringer
blocking reagent, 0.5% BSA fraction from Sigma in buffer
1) and then incubated with alkaline phosphatase-coupled
antibodies to digoxigenin (Boehringer Mannheim, Ger-
many) at a dilution of 1:700 in modified buffer 2 over-
night at 4°C. Sections were washed in buffer 1,
equilibrated in buffer 3 (100 mM Tris-base, 100 mM
NaCl, 50 mM MgCl2, adjusted to pH 9.5), and developed
in the dark with buffer 3 containing 0.34 mg/ml 4-nitrob-
lue tetrazolium chloride (Sigma), 0.175 mg/ml 5-bromo-
4-chloro-3-indolylphosphate (Sigma), and 0.25 mg/ml
levamisol (Sigma). Development was stopped by washing
with buffer 4 (10 mM Tris-HCl, 1 mM EDTA, pH 8.0), fol-
lowing which the sections were dried and mounted in
DPX beneath glass coverslips.
Quantification of OX42-labelled microglia
In three LPS-treated animals surviving 3 days, 14 days and
1 month after application of LPS, microglia were counted
in layer V of cortex under the area of LPS application and
under the area of the contralateral (control) burrhole. For
each animal, activated and ramified microglia were
counted within a counting frame of 400 µm × 340 µm
superimposed on a digital image of layer V captured using
a ×20 objective lens. The number of activated and rami-
fied microglia (means of 3 counts) was calculated as well
as the relative proportions of activated and ramified
microglia (expressed as percentages) for each survival
time (see Table 1).
Quantification of anterogradely labelled corticospinal 
tract axons
In the four LPS-treated animals in which BDA was injected
into motor cortex, and the four control animals (BDA
injected; no LPS applied), consecutive serial horizontal
sections through the entire cervical lesion site (9 sections
per animal) and 12 transverse sections through the
medulla were cut at a thickness of 40 µm and scanned
with a Leica confocal microscope. Projection images used
an accumulation of 3 scans of each optical section and
represent stacks of 20–25 optical sections merged
together, with a resolution of 1024 × 1024 pixels. The
source of these digital images was then blinded from the
quantifier. Images were standardised to 500 µm × 500
µm. For the horizontal sections, a frame was made which
hid each image from view except for a 60 µm wide win-
dow, running transversely across the image, orientated
perpendicular to the CST (corresponding to the white
boxes in Fig. 9). The total number of BDA-labelled axons
traversing this window, positioned 0.4 mm rostral to the
lesion site, were counted through the 9 serial images of
the CST. The number of axons traversing the window and
branching within it were separately recorded from the
serial horizontal sections and totalled for each animal.
The total number of labelled CST axons in each animal
was estimated by counting the number of labelled axons
in a transverse section of the medullary pyramid, photo-
graphed at a magnification of 60× (mean of counts of 3
sections).
Anterograde labelling is variable, presumably because of
variations in the uptake of BDA in the motor cortex, and
can cause bias if total numbers of labelled axons or branch
points are compared between animals. In order to nor-
malise for differences in the tracing efficiency in individ-
ual animals, the total number of branch points was
divided by the total number of labelled CST axons in the
pyramid (Fig. 10c) to give a 'total sprouting ratio' for each
animal. Another estimate of the proportion of the CST
axons sprouting near the lesion was obtained by dividing
the total number of branch points 0.4 mm rostral to theBMC Neuroscience 2006, 7:8 http://www.biomedcentral.com/1471-2202/7/8
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lesion site by the total number of axons counted 0.4 mm
rostral to the lesion site to give a 'lesion site sprouting
ratio' for each animal. After unblinding the results, the
two sets of ratios for the 4 LPS-treated animals and the 4
control animals were analysed for significant differences
by using a two-tailed unpaired Student's t-test. It should
be noted that the number of labelled CST axons counted
in the medulla gives a more accurate estimate of the total
number of axons labelled with BDA than do counts close
to the lesion site. Thus, the 'total sprouting ratio', which
utilises the medullary count, is probably a better estimate
of the injured CST regenerative response than the 'lesion
site sprouting ratio'.
Control studies
Positive controls
c-Jun and ATF3-positive nuclei were identified in the ipsi-
lateral facial nucleus, one week after facial nerve crush.
SCG10-positive cells were found in both facial nuclei, but
immunoreactivity was greater in the facial nucleus ipsilat-
eral to the crushed facial nerve. These results were consist-
ent for all animals.
Negative controls
When the primary antibody was omitted, no cells dis-
played immunoreactivity for c-Jun, ATF3 or SCG10 in
brain or facial nucleus. No positive control tissue was used
in the GAP-43 experiments; the contralateral and unoper-
ated cortex was used as a negative control.
List of Abbreviations Used
ABC Avidin Biotin Complex
BDA Biotinylated Dextran Amine
BSA Bovine serum albumin
C4 4th cervical vertebral level
C6 6th cervical vertebral level
CNS Central nervous system
CSF Cerebrospinal fluid
CST Corticospinal tract
CTB Cholera toxin – Subunit B
DABCO 1,4-diazabicyclo[2,2,2]octane
DRG Dorsal root ganglion
FG Fluorogold
GFAP Glial fibrillary acidic protein
HRP Horseradish peroxidase
LPS Lipopolysaccharide
PBS Phosphate-buffered saline
RGC Retinal ganglion cell
SCI Spinal cord injury
SSC Standard saline citrate
TBS Tris-buffered saline
TBST TBS + Triton X-100 (0.5%)
TNT TBS + Tween 20 (0.05%)
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